Fritextsökning
Innehållstyper
-
Oncozenges tablett mot munsmärta utlicensieras för Gulf-regionen
Oncozenge har ingått ett licensavtal med Dubaibaserade Avernus Pharma om kommersialisering i Gulf-regionen av Bupizenge, en sugtablett under utveckling för beha...
-
Japanese pharma to buy US drugmaker for $2.4 bln
Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.
-
Positiva data för vaccin i pulverform – ”Fungerar lika bra”
En ny studie indikerar att ett nytt influensavaccin, som utvecklas av Abera Bioscience i samarbete med Orexo, fungerar både som sprej och pulver.
-
Wusson Accelerator AB
-
Danish obesity success causes recruitment problems in southern Sweden
The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...
-
Webinar: Automate your processes
Free ZEISS webinar on January 30th, 2025.
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...
-
The Swedish Foundation for Strategic Research
-
FDA-beslut: AZ:s nasala influensavaccin får tas av patienten själv
Astra Zenecas nasala influensavaccin Flumist har godkänts för självadministrering i USA. Det är därmed det första influensavaccinet i USA som inte behöver ges av en vårdgivare.
-
From powder to implant
Quality assurance for additively manufactured implants.
-
Enhance your expertise with your measuring software
Discover the training options in our ZEISS Metrology Portal.
-
Automated nitrogen analysis reduces costs per sample
N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo
-
New large lab building in Lund inaugurated – here are the companies moving in
Medicon Village has received a new laboratory building. On Friday last week the building was inaugurated with a ribbon-cutting ceremony by Minister for Employme...
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
SupraCube - In life Science
Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...
-
MSD discontinues two Keytruda trials
MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.
-
Double up for Korbinian Löbmann
This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...
-
Marie Gårdmark: “What to expect from Trump’s second term?”
One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...
-
Conference recordings now available
Don't miss out on insights from leading experts.
-
Mastering Urine Microscopy
On-demand Webinar: Microscopy in urinalysis.
-
Several departures at the top at Nykode
Members of both the management and the board are leaving the Norwegian biotech company Nykode.
-
Takeover bid is being completed – Japanese company acquires Calliditas
Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...
-
Inget statligt stöd för fetmaläkemedel – aktien för läkemedelsjättar pressas
Trump-administrationen slopar Bidens förslag om att om att inkludera fetmaläkemedel i sjukförsäkringen Medicare. Det innebär ett bakslag för Novo Nordisk och El...